AVNSMEDIUM SIGNALOPERATIONAL10-K

Avanos Medical restructured from one operating segment to two reportable segments (Specialty Nutrition Systems and Pain Management), while significantly reducing operating losses by 84.5%.

The reorganization into two distinct segments suggests management is repositioning the business for clearer operational focus and potentially improved performance measurement. The dramatic improvement in operating losses indicates either successful cost reduction initiatives or one-time charges in the prior year that didn't repeat, though the specific drivers aren't clear from this data alone.

Comparing 2026-02-24 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

The company showed substantial improvement with operating losses decreasing 84.5% and net losses declining 81.4%, representing a significant turnaround in profitability metrics. However, this improvement came alongside concerning trends including a 25.8% decline in operating cash flow, reduced cash reserves, and 50% higher interest expense. While the loss reduction is encouraging, the deteriorating cash generation and higher financing costs suggest the operational improvements may not yet be translating to sustainable cash flow performance.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+84.5%
-$396.2M→-$61.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+81.4%
-$392.1M→-$72.9M

Net income grew 81.4% — bottom-line growth signals improving overall business health.

Share Buybacks
Cash Flow
-74.2%
$12.8M→$3.3M

Buyback activity reduced 74.2% — capital being redeployed elsewhere or cash conservation underway.

Interest Expense
P&L
+50%
$10.0M→$15.0M

Interest expense surged 50% — significant debt increase or rising rates materially impacting earnings.

Total Debt
Balance Sheet
-27.9%
$125.3M→$90.3M

Debt reduced 27.9% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
-25.8%
$100.7M→$74.7M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
-16.6%
$107.7M→$89.8M

Cash decreased 16.6% — monitor burn rate and upcoming capital needs.

R&D Expense
P&L
-11.1%
$26.2M→$23.3M

R&D spending cut 11.1% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-26
ADDED
As of February 17, 2026 , there were 46,503,458 shares of Avanos Medical, Inc.
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.
We conduct our business in two operating and reportable segments that provide our medical device products to healthcare providers and patients.
We have manufacturing facilities in the United States, Mexico and Canada.
Within our reportable segments, we provide a portfolio of innovative product offerings focused on Specialty Nutrition Systems and Pain Management and Recovery to improve patient outcomes and reduce the cost of care.
Specialty Nutrition Systems ( SNS ) is a portfolio of products including: Enteral feeding, which includes products such as our MIC-KEY enteral feeding tubes and Corpak patient feeding solutions.
Neonate solutions, which includes NeoMed neonatal and pediatric feeding solutions and Nexus TKO anti-reflux needleless connectors.
In the years ended December 31, 2025, 2024 and 2023, our NeoMed neonatal and pediatric feeding solutions (the NeoMed Products ) accounted for more than 10% of our consolidated net sales.
In the year ended December 31, 2023, our ON-Q surgical pain pump individually accounted for more than 10% of our consolidated net sales.
Radiofrequency Ablation ( RFA ) solutions, which provide minimally invasive pain-relieving therapies, such as our COOLIEF pain therapy products (the COOLIEF Products ) and our Trident and ESENTEC RFA products used to treat chronic pain conditions.
REMOVED
As of February 19, 2025 , there were 46,003,150 shares of Avanos Medical, Inc.
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 7A.
Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of our management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished.
We conduct our business in one operating and reportable segment that provides our medical device products to healthcare providers and patients.
We have manufacturing facilities in the United States and Mexico.
Within our single reportable segment, we provide a portfolio of innovative product offerings focused on Digestive Health and Pain Management and Recovery to improve patient outcomes and reduce the cost of care.
Digestive Health is a portfolio of products that includes our MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions.
In the year ended December 31, 2022, our MIC-KEY Products and our NeoMed Products each accounted for more than 10% of our consolidated net sales.
In each of the years ended December 31, 2023 and 2022, our ON-Q surgical pain pump individually accounted for more than 10% of our consolidated net sales.
Interventional pain solutions, which provide minimally invasive pain relieving therapies, such as our COOLIEF chronic pain products (the COOLIEF Products ), our OrthogenRx knee osteoarthritis hyaluronic acid ( HA ) pain relief injection products (GenVisc and TriVisc) and our Trident radiofrequency ablation ( RFA ) products used to treat chronic pain conditions.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →